Short Interest in ESSA Pharma Inc (NASDAQ:EPIX) Drops By 23.0%

ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) saw a significant decrease in short interest in December. As of December 31st, there was short interest totalling 92,500 shares, a decrease of 23.0% from the December 15th total of 120,100 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average trading volume of 41,000 shares, the short-interest ratio is currently 2.3 days.

EPIX has been the subject of several recent analyst reports. ValuEngine lowered ESSA Pharma from a “hold” rating to a “sell” rating in a report on Saturday, October 19th. Oppenheimer initiated coverage on ESSA Pharma in a report on Thursday, October 24th. They issued an “outperform” rating and a $8.00 target price for the company.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Orbimed Advisors LLC bought a new position in ESSA Pharma during the third quarter valued at $4,960,000. Eventide Asset Management LLC grew its holdings in ESSA Pharma by 45.1% during the third quarter. Eventide Asset Management LLC now owns 2,010,169 shares of the company’s stock valued at $6,436,000 after purchasing an additional 625,000 shares during the period. Finally, Commonwealth Equity Services LLC bought a new position in ESSA Pharma during the third quarter valued at $38,000. 83.48% of the stock is owned by institutional investors and hedge funds.

Shares of EPIX stock traded up $0.02 during trading on Tuesday, hitting $5.87. The company’s stock had a trading volume of 11,335 shares, compared to its average volume of 20,144. The company has a market cap of $84.42 million, a PE ratio of -4.02 and a beta of 2.03. The business has a fifty day moving average of $5.49 and a 200-day moving average of $3.67. ESSA Pharma has a 52 week low of $1.41 and a 52 week high of $6.14.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last announced its quarterly earnings data on Thursday, December 19th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.09. On average, sell-side analysts expect that ESSA Pharma will post -0.72 EPS for the current fiscal year.

About ESSA Pharma

ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Recommended Story: What is required to own or exchange cryptocurrency?

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.